2 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
Follow Healthy Subject: new trials by email Literature Review of Healthy Subject trials Research Report on Healthy Subject
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Orelabrutinib and placebo (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib tablet simulator) - Healthy Subject | Phase 1 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 48 | 2022-11-19 | 2022-12-21 |
| Dose Escalating Study of BPI-3016 in Healthy Subjects BPI-3016, Placebo - Healthy Subject | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 63 | 2017-05-24 | 2019-01-02 |
BPI-3016 (1) · Moxifloxacin (1) · orelabrutinib (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · Betta Pharmaceuticals Co., Ltd. (1)
China (2)